Previous 10 | Next 10 |
home / stock / acog:cc / acog:cc news
NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from Life Science Investor Forum, held on June 22 nd are now available for online viewing. REGISTER NOW AT : https://...
Toronto, Ontario--(Newsfile Corp. - June 20, 2023) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for May 2023. May 2023 Operating Statistics Trading volume of CSE-listed securities totaled 1.25 billion shares; Trading value of CSE-listed secu...
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGIST...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the that it has been awarded a $750,000 grant f...
Not for distribution in the U.S. or to U.S. newswire services. Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the l...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”) announces a private placement offering of up to $6,500,000 of units at a price of $0.22 per unit. Each unit will consist of one common share and one-half of a share purchase warrant. ...
--News Direct-- Alpha Cognition CEO Michael McFadden joins Natalie Stoberman from the Proactive studio to discuss the company's latest financial growth from new funding and reduced expenses and how its been highlighted by a new listing on the Canadian Stock Exchange. Alpha Cognition i...
Toronto, Ontario--(Newsfile Corp. - Le 28 avril/April 2023) - The common shares and warrants of Alpha Cognition Inc. have been approved for listing on the CSE. Listing and disclosure documents will be available at www.thecse.com on the trading date. Alpha Cognition Inc. is a clinical sta...
VANCOUVER, BC / ACCESSWIRE / April 5, 2023 / Alpha Cognition Inc. (TSX-V:ACOG)(OTCQB:ACOGF), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday,...
Not for distribution in the United States or to U.S. newswire services Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders...
News, Short Squeeze, Breakout and More Instantly...
Alpha Cognition Inc. Company Name:
ACOG:CC Stock Symbol:
TSXVC Market:
Alpha Cognition Inc. Website:
The Second Oral Therapy Approved This Decade, ZUNVEYL’s Dual MOA Was Designed to Eliminate Drug Absorption in the Gastrointestinal (GI) Tract, Potentially Addressing Certain Tolerability Issues with Leading Alzheimer’s Disease (AD) Medications, Combined with a Long-Term Efficacy Pro...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...